<DOC>
	<DOC>NCT00279760</DOC>
	<brief_summary>This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA</brief_summary>
	<brief_title>Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis of RA &lt; 5 years Functional class I, II, or II as defined by the American College of Rheumatology (ACR) criteria. Must have failed at least 1 Disease Modifying AnitRheumatic Drug (DMARD) Joint count of 10 or more swollen and 12 or more tender. Erythrocyte Sedimentation Rate (ESR) &gt; 28mm/rr or norning stiffness &gt; 45 minutes. Women and men who are not willing to use an accepted form of contraception. Active vasculitis Treatment with another investigational drug within 30 days History of asthma, angioedema, or anaphylaxix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>